A retrospective analysis of 194 consecutive memory-clinic patients sent for amyloid PET compared positivity across subjective complaints, mild cognitive impairment and early Alzheimer's disease. Positivity rose stepwise, from 40.9% in those with subjective complaints to 66.0% in mild cognitive impairment. It reached 91.7% in early Alzheimer's disease, and MRI measures of brain shrinkage added nothing to the clinical diagnosis in predicting amyloid positivity.
Why it is interesting: Two in five with complaints but no measured impairment were amyloid-positive, so a biological definition would count them.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.